SavedAdd your journal

Journals / art / 2015 / Cilt: 30 - Sayı: 3

Prevalence of Extraglandular Manifestations in Patients With Primary Sjögren's Syndrome in Southern Norway: A Comparison to the Literature

Lars JORKJEND
Anders JOHANSSON
Ann Katrin JOHANSSON
Journal
art
Pages
263–270
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our findings suggest that studies including larger sample sizes may be subjected to underreporting.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the prevalence of extraglandular manifestations (EGM) in a group of Norwegian patients suffering from primary Sjögren’s syndrome (pSS) and compare these findings with the literature.
📊
Key Findings & Data:Material and methods: Fifty-three female patients (mean age 60±11.6 years; range 33 to 85 years) fulfilling the clinical criteria for pSS were included in the study.
💡
Conclusion & Impact:Our findings suggest that studies including larger sample sizes may be subjected to underreporting.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to investigate the prevalence of extraglandular manifestations (EGM) in a group of Norwegian patients suffering from primary Sjögren’s syndrome (pSS) and compare these findings with the literature. Material and methods: Fifty-three female patients (mean age 60±11.6 years; range 33 to 85 years) fulfilling the clinical criteria for pSS were included in the study. To investigate the prevalence of EGM, a PubMed search from April 1976 to August 2012 identified 100 relevant publications by 88 authors, comprising a total of 14,861 pSS patients. An attempt was made to compare the obtained results regarding the prevalence of EGM with our results. Results: In our study group, mean prevalence rate of EGM was 42.1% with a range from 0 to 92.5% compared to the range of 0.8 to 94% in the PubMed reports on EGM. Epidemiological studies involving large groups of patients tend to yield lower prevalence of EGM than studies based on a smaller sample size. We were unable to compare the reports of prevalence of EGM in patients with pSS due to different methodologies and classification criteria applied in the different studies. Conclusion: The prevalence of pSS in this study was within the range of that reported in the literature. Due to methodological issues, we were unable to compare reports of prevalence of EGM in pSS. Our findings suggest that studies including larger sample sizes may be subjected to underreporting.

🔖

Cite This Article

JORKJEND, L., JOHANSSON, A., JOHANSSON, A. K. (2015). Prevalence of Extraglandular Manifestations in Patients With Primary Sjögren's Syndrome in Southern Norway: A Comparison to the Literature. art, Cilt: 30 - Sayı: 3, 263–270. https://ajindex.com/articles/347965

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004;33:39-43
  2. Birlik M, Akar S, Gurler O, Sari I, Birlik B, Sarioglu S, et al. Prevalence of primary Sjogren’s syndrome in Turkey: a population-based epidemiological study. Int J Clin Pract 2009;63:954-61
  3. Kruize AA, Hené RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP, et al. Longterm followup of patients with Sjögren’s syndrome. Arthritis Rheum 1996;39:297-303
  4. Asmussen K, Andersen V, Bendixen G, Schiødt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med 1996;239:475-82
  5. Mahoney EJ, Spiegel JH. Sjögren’s disease. Otolaryngol Clin North Am 2003;36:733-45
  6. Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch JA, Toussirot E, et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 2005;84:81-9
  7. Hansen A, Dörner T. Sjögren syndrome. Internist (Berl) 2010;51:1267-79
  8. Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjögren’s syndrome. Ann Rheum Dis 2005;64:1062-4
  9. Jonsson R, Bowman SJ, Gordon TP. Sjøgren’s syndrome. In: Koopman WJ, Moreland LW, editors. Arthritis and Allied Conditions. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1681-705
  10. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7. 11. de Vet HC, Terwee CB, Bouter LM. Current challenges in clinimetrics. J Clin Epidemiol 2003;56:1137-41
  11. Manthorpe R, Jacobsson LT, Kirtava Z, Theander E. Epidemiology of Sjögren’s syndrome, especially its primary form. Ann Med Interne (Paris) 1998;149:7-11
  12. Hernández-Molina G, Sánchez-Hernández T. Clinimetric methods in Sjögren’s syndrome. Semin Arthritis Rheum 2013;42:627-39
  13. Asmussen K, Andersen V, Bendixen G, Bendtzen K, Prause JU, Thorn J, et al. Quantitative assessment of clinical disease status in primary Sjögren’s syndrome. A cross-sectional study using a new classification model. Scand J Rheumatol 1997;26:197-205
  14. Vitali C, Palombi G,